Researchers at the Swiss Federal Laboratories for Materials Science and Technology in Dübendorf, Switzerland, have developed an AI-powered computer model of a laboratory mouse that uses machine learning to predict how various nanomaterials distribute within the mouse’s body. In the future, the model is intended not only to serve as a decision-making tool in drug development but also to reduce the number of animal experiments. 

Researchers at the Helmholtz Zentrum München, the Technical University of Munich (TUM), the Stowers Institute for Medical Research, and the University of Oxford have developed an AI-based model called “RegVelo.” RegVelo not only tracks the developmental pathways of cells but also simulates how these pathways change.

Forscher am Helmholtz-Zentrum München, der Technischen Universität München (TUM), dem Stowers Institute for Medical Research und der Universität Oxford haben ein KI-basiertes Modell unter dem Namen „RegVelo" entwickelt. RegVelo kann nicht nur Entwicklungswege von Zellen nachverfolgen, sondern auch simulieren, wie sich diese Wege verändern.  

A team led by Prof. Gil Westmeyer, Director of the Institute for Synthetic Biomedicine (ISBM) at Helmholtz Munich, has developed a new method for repeatedly obtaining up-to-date genetic information from living cells without destroying them. This will in future enable better monitoring of stem cells for therapies or the effects of drugs within the cells.